Edition:
United Kingdom

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

4.85USD
15 Dec 2017
Change (% chg)

$0.15 (+3.19%)
Prev Close
$4.70
Open
$4.75
Day's High
$4.90
Day's Low
$4.65
Volume
26,378
Avg. Vol
21,701
52-wk High
$7.20
52-wk Low
$3.55

Select another date:

Mon, Dec 4 2017

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:

BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE

BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27

* Axsome Therapeutics reports third quarter 2017 financial results

BRIEF-Axsome enters agreement to sell up to $30 mln of shares of co's common stock

* Axsome Therapeutics-entered sales agreement to sell through leerink up to $30 million of shares of co's common stock,par value $0.0001/share-SEC filing Source text : (http://bit.ly/2gxqvzm) Further company coverage:

BRIEF-Axsome Therapeutics reports Q2 loss per share $0.30

* Axsome Therapeutics reports second quarter 2017 financial results

BRIEF-Axsome Therapeutics announces AXS-06 meets primary endpoint in phase 1 clinical trial

* Axsome Therapeutics announces AXS-06 (moseic meloxicam and esomeprazole) meets primary endpoint in phase 1 clinical trial

BRIEF-Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation

* Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation Source text for Eikon: Further company coverage:

BRIEF-Axsome appoints John Golubieski as CFO

* Axsome Therapeutics appoints John Golubieski as chief financial officer

Select another date: